Moderna, Inc. (MRNA) Net margin 2016–2025
Moderna, Inc. (MRNA) net profit margin by fiscal year — reported net income divided by reported revenue.
-145.2%FY2025 · since FY2016: -199.5% → -145.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -145.2% | -35.1 pp |
| FY2024 | -110.0% | -41.2 pp |
| FY2023 | -68.8% | -112.2 pp |
| FY2022 | 43.4% | -22.7 pp |
| FY2021 | 66.1% | +159.1 pp |
| FY2020 | -93.0% | +760.7 pp |
| FY2019 | -853.7% | -568.8 pp |
| FY2018 | -284.8% | -160.5 pp |
| FY2017 | -124.3% | +75.1 pp |
| FY2016 | -199.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More MRNA financial trends
MRNA RevenueMRNA Net incomeMRNA Gross profitMRNA Gross marginMRNA Operating incomeMRNA Operating marginMRNA Operating cash flowMRNA Free cash flowMRNA Capital expendituresMRNA Return on equityMRNA Stock buybacksMRNA Dividends paidMRNA Total assetsMRNA Total liabilitiesMRNA Shareholders’ equityMRNA overview →